Janux Therapeutics opened lower at $11.86, compared with its previous close of $12.39. In the last trading session, the stock traded between $11.50 and $11.99. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Janux Therapeutics is now worth
$ 46.18
Resulting in a loss of
$ 53.82 (53.82%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 12 Analysts
Buy
83.33%
Hold
8.33%
Sell
8.33%
Markets Today
Today's Change
$-0.90 (-7.26%)
Day High
$11.99
Day Low
$11.50
Day Open
$11.86
Prev Close
$12.39
Volume
9,23,314
1W Return
-36.76%
1M Return
-36.77%
3M Return
-30.35%
6M Return
-19.26%
1Y Return
-60.20%
Fundamentals
Market Cap ($ Mn)
703
PE Ratio
-
PB Ratio
1.19
PEG Ratio
-
ROE
-11.46%
ROCE
-15.57%
EPS (TTM)
$-0.35
Investment Returns
1 Week
-36.76%
1 Month
-36.77%
3 Months
-30.35%
6 Months
-19.26%
9 Months
-12.36%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
10.0
Sep 25
0.0
Dec 25
10.3
Jun 26
9.3
Sep 26
Updates
12Nov
Wolfe Research downgrades Janux Therapeutics to Peer Perform
Wolfe Research downgraded Janux Therapeutics from Outperform to Peer Perform. Analyst Kalpit Patel issued the rating change. No specific financial figures or price targets were disclosed in the source.
Single 3 mg dose produced >90% peripheral B-cell depletion in most participants. All cytokine release syndrome events were Grade 1; no serious adverse events reported. B-cell reductions persisted through Day 42, with two participants below limit of detection. Janux plans to initiate autoimmune studies for immune thrombocytopenia and rheumatoid arthritis in 2027.
3 days ago
6Nov
Barclays raises Janux Therapeutics price target to $15, keeps Underweight
Barclays maintains Underweight rating on Janux Therapeutics. Price target raised from $14 to $15 by analyst Etzer Darout.
6 days ago
14Sep
Janux Therapeutics doses first patient in Phase 1 trial for JANX013
Janux Therapeutics doses first patient in Phase 1 trial for JANX013. Study evaluates JANX013 plus JANX007 in metastatic castration-resistant prostate cancer. Trial aims to assess safety, pharmacokinetics, and T-cell persistence biomarkers. Mechanism uses tumor-activated CD28 co-stimulation to enhance immune durability.
1mo ago
24Aug
Wolfe Research upgrades Janux Therapeutics to Outperform, sets $23 target
Wolfe Research upgrades Janux Therapeutics (NASDAQ: JANX) to Outperform. Previous rating was Peer Perform. New price target set at $23.
2mo ago
8Aug
Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $55
Guggenheim analyst Brad Canino maintains a Buy rating on Janux Therapeutics but lowers the price target from $58 to $55. The revision reflects a calibrated valuation outlook while preserving confidence in the company’s long-term prospects.
